Hematocrit Tests Market

Haematocrit Tests Market Overview (2022 to 2032)

The global Haematocrit Tests Market was valued at around US$ 4,035.6 Million at the end of 2021. The market is projected to register a 4.3 % CAGR and top a valuation of US$ 6,427.6 Million by 2032.

The global Haematocrit tests market is expanding because of the rising incidence of disorders like diabetes, cancer, cardiovascular, kidney, and other blood-related illnesses.

The haematocrit test measures the volume of red blood cells about the volume of all the blood (red blood cells and plasma). Direct measurement of this value using microhaematocrit centrifugation. Haematocrit tests are also known as HCT, packed cell volume (PCV), Haemoglobin and Haematocrit. Throughout the forecast period, significant growth is anticipated for the worldwide haematocrit test market.

Haematocrit test market growth is expected to be lucrative due to the rise in the prevalence of chronic diseases that can lead to blood problems, including cardiac disorders, kidney disorders, and others.

One of the key reasons propelling the growth of the haematocrit test devices market globally is the rising elderly population and the rise in blood-related disorders among the senior population. Additionally, the rise in anaemia cases, other chronic diseases that cause anaemia, and technological developments backed by government funding and initiatives are all expected to contribute to the market's expansion.

Attributes	Details
Haematocrit tests market value in 2021	US$ 4,035.6 Million
Haematocrit tests market value in 2032	US$ 6,427.6 Million
Haematocrit tests market CAGR (2022 to 2032)	4.3 %

What are the Major Drivers Boosting the Demand for Haematocrit Tests Market?

During the projected period, the market for haematology tests is anticipated to expand rapidly. The global market for haematology testing is expanding as a result of several factors, including the development of technologically sophisticated haematology analyzers, an increase in the use of flow cytometry in haematology testing, and the creation of high-sensitivity point-of-care haematology analyzers.

Due to the rise in blood-related disorders among COVD-infected individuals, the COVID-19 impact is anticipated to have a beneficial effect on the market. For instance, the article Anaemia predicts poor results of COVID-19 in hospitalised patients published in 2021 said that anaemia was prevalent and associated with bad outcomes of COVID-19 in hospitalised patients. As a result, there was a greater need for haematocrit test instruments among COVID-19-infected individuals due to the rising prevalence of blood-related disorders.

The increasing use of the haematocrit test, research and development activities combined with technological advancements in medical equipment, and other factors are also propelling the growth of the haematocrit test market. For instance, user-friendly point-of-care haematocrit tests, lab automation, automated sample collection, test identification, and others.

Which Region Shows Strong Growth Potential in the Haematocrit Tests Market?

The Haematocrit tests market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.

Due to the widespread use of haematocrit tests in conjunction with other diagnostic procedures and the high prevalence of chronic diseases, North America commands the lion's share of the global market for haematocrit test equipment. Anaemia is the most prevalent blood illness and affects more than 3 million Americans, according to a 2022 publication from the American society of haematology.

Companies that are involved in the production and marketing of haematology analyzers and reagents are finding new sources of income in developing markets like China, India, Brazil, and Mexico. The growing patient population, rising healthcare expenses, and an increase in medical tourism because of affordable treatments are the key factors driving the demand for haematological tests in these emerging nations.

Who are the Key Players in the Haematocrit Tests Market?

Abbott Laboratories, Boule Diagnostics AB, Danaher Corporation, EKF Diagnostics, F. Hoffmann-La Roche Ltd., HORIBA, Ltd., Nova Biomedical, Sysmex Corporation., Siemens Healthcare GmbH, Thermo Fisher Scientific, among others.

Scope of Report

Report Attributes	Details
Growth Rate	CAGR of 4.3 % from 2022 to 2032
Base Year for Estimation	2021
Historical Data	2012 to 2021
Forecast Period	2022 to 2032
Qualitative Units	Revenue in USD Million, and CAGR from 2022 to 2032
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segment Covered	By Product By Indication By End User By Region
Region Covered	North America Latin America Europe East Asia South Asia Oceania Middle East & Africa
Key Countries Profiled	USA Canada Brazil Mexico Germany UK France Spain Italy India China Japan South Korea Malaysia Singapore Australia New Zealand GCC Countries South Africa Israel
Key Players	Abbott Laboratories Boule Diagnostics AB Danaher Corporation EKF Diagnostics F. Hoffmann-La Roche Ltd. HORIBA, Ltd. Nova Biomedical Sysmex Corporation Siemens Healthcare GmbH, Thermo Fisher Scientific Others
Customization	Available Upon Request

Key Segments Covered in the Haematocrit Tests Market Report

Haematocrit Tests Market by Product:

• Haematocrit Test Analyzers
• Haematocrit Test Meters
• Consumables

Haematocrit Tests Market by Indication:

• Anaemia
• Polycythaemia
• Vitamin Deficiencies
• Others

Haematocrit Tests Market by End User:

• Hospitals
• Diagnostics Centres
• Clinics
• Homecare Settings

Haematocrit Tests Market by Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa (MEA)